Deca 200 mg/NPP 150 mg is an oil-based injectable blend of Nandrolone Decanoate and Nandrolone Phenylpropionate manufactured by Dragon Pharma and dosed at 350 mg/mL in a 10 mL vial.
Deca 200 mg/NPP 150 mg combines two esters of the 19-nor anabolic steroid nandrolone in a single injectable formulation: nandrolone decanoate (200 mg/mL) and nandrolone phenylpropionate (150 mg/mL). Nandrolone decanoate is an FDA-approved ester for the management of anemia of renal insufficiency and has been shown to increase hemoglobin and red cell mass. Nandrolone phenylpropionate is a shorter-acting nandrolone ester that targets the androgen receptor and is classified as an anabolic agent.
Each ester contributes distinct release characteristics to the blend. Nandrolone decanoate has a long half-life of approximately 15 days, providing sustained release over weeks. Nandrolone phenylpropionate has a shorter half-life of approximately 2-3 days, providing a more rapid onset of action. The combination is designed to deliver both a rapid initial effect and a prolonged anabolic environment. In non-medical bodybuilding contexts, nandrolone esters are commonly referenced for their ability to promote muscle mass gains, joint comfort, and recovery during bulking or off-season cycles.
Nandrolone differs structurally from testosterone by lacking a carbon-19 methyl group, which contributes to its relatively lower androgenic activity compared to testosterone. Both esters ultimately release the same active hormone, nandrolone. Nandrolone decanoate is classified as a Schedule III controlled substance under the Anabolic Steroids Control Act of 1990. Non-medical use of this blend falls outside approved indications and may carry significant health risks, including cardiovascular and hepatic complications.
Deca 200 mg/NPP 150 mg uses MCT oil as its carrier, providing an oil base for the dual-ester nandrolone blend. The 350 mg/mL total concentration delivers 200 mg of nandrolone decanoate and 150 mg of nandrolone phenylpropionate per mL.
Deca 200 mg/NPP 150 mg is a dual-ester blend combining two nandrolone preparations with different release profiles. The decanoate ester provides extended release, while the phenylpropionate ester provides a shorter, more rapid release.
Nandrolone is a 19-nortestosterone derivative that binds to the androgen receptor and is classified pharmacologically as an androgen and anabolic agent. The decanoate ester attached to the 17-beta hydroxyl group produces a long-acting depot formulation with a half-life of approximately 15 days. Pharmacokinetic studies in healthy men have demonstrated that nandrolone decanoate produces sustained plasma nandrolone concentrations with the most sustained suppression of endogenous testosterone and inhibin occurring after gluteal injection.
Nandrolone phenylpropionate is a shorter-acting ester with higher and earlier peak plasma concentrations compared to the decanoate ester. This ester targets the androgen receptor and is classified under the ATC code A14AB01 (nandrolone derivatives). The combination of both esters in a single formulation is designed to provide a rapid initial rise in nandrolone levels from the phenylpropionate component, followed by a sustained release from the decanoate component.
Nandrolone decanoate is indicated for the management of anemia of renal insufficiency and has been shown to increase hemoglobin and red cell mass. It is also used in clinical settings for osteoporosis, where it acts as an inhibitor of bone resorption. Non-medical use for physique enhancement is not approved and carries significant risks.
The dual-ester design of Deca 200 mg/NPP 150 mg produces a two-phase release profile. The phenylpropionate component provides a relatively rapid rise in blood nandrolone levels, with earlier and higher peaks compared to the decanoate ester alone. The decanoate component then provides sustained release over approximately 15 days, maintaining elevated nandrolone levels for an extended period. In non-medical contexts, this blend is typically referenced as being administered once or twice per week.
Dragon Pharma offers individual nandrolone preparations for users who prefer to control each ester separately. The Deca 300 provides nandrolone decanoate at 300 mg/mL as a single-ester formulation, while NPP 150 provides nandrolone phenylpropionate at 150 mg/mL. The dual-ester blend in Deca 200 mg/NPP 150 mg combines both in a fixed ratio that cannot be adjusted without additional standalone products.
In non-medical bodybuilding contexts, nandrolone esters are frequently stacked with a testosterone base such as Cypionate 250. Aromatase inhibitors may be referenced when the testosterone component produces estrogenic effects. Nandrolone suppresses endogenous testosterone production, so a testosterone base is commonly referenced in non-medical cycles.
Published laboratory reports for Deca 200 mg/NPP 150 mg are shown below with the test date, measured concentration and percentage of the product's label claim for each component.
View Report
Laboratory results apply to the specific tested sample represented in each published report and should not be interpreted as a measurement of every vial or production batch.
The information below is provided for educational reference only. Nandrolone decanoate is a prescription medication; medical use requires appropriate diagnosis, clinical supervision and ongoing monitoring. Non-medical use falls outside approved indications.
In medically supervised use, nandrolone decanoate is dosed at 100 to 200 mg per week for men and 50 to 100 mg per week for women, with therapy discontinued if no hematologic improvement is seen within the first six months. In non-medical bodybuilding contexts, nandrolone esters are commonly referenced in the range of 200–400 mg per week for general use, with experienced users sometimes referencing higher amounts. One reference guide lists 200-250 mg once per week as a common protocol. The 350 mg/mL concentration of Deca 200 mg/NPP 150 mg means that 1 mL provides 200 mg nandrolone decanoate and 150 mg nandrolone phenylpropionate.
| Use Case | Common Reference Range | Injection Frequency |
|---|---|---|
| Medical (anemia of renal insufficiency) | 100–200 mg / week (men) | Per prescriber instructions |
| Bodybuilding (non-medical) | 200–400 mg / week | Once or twice weekly |
| Joint support (non-medical) | Often 100–200 mg / week | Once weekly |
In non-medical bodybuilding contexts, nandrolone blends are frequently referenced alongside a testosterone base compound. Dragon Pharma's Cypionate 250 is commonly mentioned in this context. Nandrolone is also sometimes combined with oral compounds during bulking cycles. The dual-ester design of Deca 200 mg/NPP 150 mg provides both rapid and sustained release, which may be referenced as an advantage for maintaining stable blood levels.
Nandrolone decanoate has a long detection time and can suppress endogenous testosterone production. Cycle structure, duration, and recovery considerations should account for these characteristics. Because the blend contains two esters with different half-lives, clearance after the final injection takes several weeks.
Nandrolone can suppress gonadotropic functions of the pituitary and may exert a direct effect upon the testis, leading to reduced sperm production and testicular atrophy. Sexual dysfunction is a recognized risk, particularly without appropriate management. Nandrolone decanoate has been reported to increase low-density lipoproteins and decrease high-density lipoproteins.
Nandrolone is not a 17-alpha-alkylated oral steroid and therefore is not considered hepatotoxic in the same manner as oral C17-alpha-alkylated compounds. However, peliosis hepatis and liver cell tumors have been reported in patients receiving androgenic anabolic steroid therapy. Blood pressure and cardiovascular markers should be monitored during use.
After completing a cycle with Deca 200 mg/NPP 150 mg, post-cycle therapy is commonly recommended in non-medical contexts to help restore endogenous testosterone production. Because the blend contains the long-acting decanoate ester, PCT should begin approximately 2–3 weeks after the final injection to allow the ester to clear. Agents such as Clomid or Nolvadex are frequently referenced for this purpose. Bloodwork and, where possible, medical guidance can help inform recovery strategy.
Dosing strategies, support compounds and recovery protocols should be adjusted based on experience level and bloodwork where possible. The information above is for educational reference and does not constitute medical advice.
Nandrolone decanoate is a Schedule III controlled anabolic steroid that can affect hematologic, cardiovascular, hepatic and reproductive function. Nandrolone phenylpropionate is also a controlled substance. Medical use requires appropriate diagnosis, clinical supervision and ongoing monitoring.
Nandrolone decanoate is indicated for the management of anemia of renal insufficiency and has been shown to increase hemoglobin and red cell mass. It has not been shown to be safe and effective for the enhancement of athletic performance, and the FDA label states it should not be used for such purpose. Nandrolone decanoate injection is classified as a Schedule III controlled substance under the Anabolic Steroids Control Act of 1990.
Peliosis hepatis, a condition in which liver and sometimes splenic tissue is replaced with blood-filled cysts, has been reported in patients receiving androgenic anabolic steroid therapy. These cysts are sometimes present with minimal hepatic dysfunction, but at other times they have been associated with liver failure.
Use of nandrolone esters for bodybuilding or performance enhancement falls outside approved medical indications. Higher-than-physiologic exposure can increase the risk of serious adverse effects including cardiovascular, hepatic and endocrine complications.
Anabolic steroids including nandrolone have been reported to increase low-density lipoproteins and decrease high-density lipoproteins. These changes may have a serious impact on the risk of atherosclerosis and coronary artery disease. Blood lipid changes known to be associated with increased risk of atherosclerosis are seen in patients treated with androgens and anabolic steroids.
Nandrolone suppresses gonadotropic functions of the pituitary and may exert a direct effect upon the testis, leading to inhibition of testicular function, testicular atrophy, oligospermia, and impotence. In women, virilization signs such as deepening of the voice, hirsutism, acne, and clitoromegaly may occur and can be irreversible if the drug is continued after symptoms appear.
Edema may occur occasionally with or without congestive heart failure. Cholestatic jaundice is associated with therapeutic use of anabolic and androgenic steroids. Caution is required in administering these agents to patients with cardiac, renal or hepatic disease.
Anabolic steroids are contraindicated in certain circumstances. Contraindications include male patients with carcinoma of the prostate or breast, carcinoma of the breast in females with hypercalcemia, nephrosis, the nephrotic phase of nephritis, and pregnancy. Nandrolone decanoate should not be used to enhance physical appearance or athletic performance.
Caution is required in administering anabolic steroids to patients with cardiac, renal or hepatic disease. Existing medical conditions should be discussed with a qualified healthcare professional before nandrolone is considered.
Medically supervised nandrolone decanoate therapy typically involves periodic laboratory monitoring. Hemoglobin and hematocrit should be checked periodically for polycythemia in patients receiving high doses. Serum lipids and high-density lipoprotein cholesterol should be determined periodically. Because of the hepatotoxicity associated with 17-alpha-alkylated anabolic steroids, liver function tests should be obtained periodically.
Laboratory testing of the product itself, such as the published potency reports shown in the Lab Reports tab, is separate from clinical monitoring of the person using the medication.
Keep the vial securely stored and protected from conditions that could compromise the product or container. Store at controlled room temperature and protect from light. Inspect the vial and solution before use and do not use a product that appears damaged, contaminated or otherwise abnormal.
Keep all medications and injectable products out of the reach of children. Follow the storage instructions provided with the product packaging.
Deca 200 mg/NPP 150 mg by Dragon Pharma is shipped in original manufacturer packaging with discreet, privacy-focused handling.
The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details.
To verify your Deca 200 mg/NPP 150 mg product, use the security code on the vial label and cross-check it on the Dragon Pharma official site. Original Dragon Pharma packaging and batch-linked lab proof help reinforce product legitimacy.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Proper storage conditions help preserve formulation stability and overall product integrity throughout shelf life.
Store at controlled room temperature (15–25°C) and protect from excessive heat, moisture, and direct light. Maintaining stable conditions helps preserve the integrity of the oily formulation.
Keep the vial in its original packaging until use. Do not freeze. Before administration, inspect the solution and avoid use if it appears cloudy, discolored, contains particulate matter, or if the vial or seal is compromised.
Keep out of reach of children. Follow proper handling and sterile injection practices when administering the product.
Answers to common questions about Deca 200 mg/NPP 150 mg, the dual-ester nandrolone blend, usage considerations, and product strength.
Deca 200 mg/NPP 150 mg contains nandrolone decanoate and nandrolone phenylpropionate. Nandrolone decanoate is medically indicated for the management of anemia of renal insufficiency. In non-medical bodybuilding settings, this blend is commonly referenced for muscle mass gains, joint comfort, and recovery during bulking cycles, though such use falls outside approved indications.
Because the blend contains both a long-acting decanoate ester and a shorter-acting phenylpropionate ester, it is typically referenced as being administered once or twice per week in non-medical contexts. The 350 mg/mL concentration means that 1 mL provides 200 mg nandrolone decanoate and 150 mg nandrolone phenylpropionate.
In non-medical bodybuilding contexts, post-cycle therapy is commonly recommended after a nandrolone cycle to help restore endogenous testosterone production. Because the blend contains the long-acting decanoate ester, PCT should begin approximately 2-3 weeks after the final injection. Agents such as Clomid or Nolvadex are commonly referenced for this purpose.
Both esters release the same active hormone, nandrolone, which binds to the androgen receptor and promotes nitrogen retention and protein synthesis. The decanoate ester provides a long-acting depot with a half-life of approximately 15 days, while the phenylpropionate ester provides a shorter, more rapid release with higher and earlier peak plasma concentrations.
Because of the dual-ester design, the phenylpropionate component provides a relatively rapid rise in nandrolone levels, while the decanoate component provides sustained release over weeks. In non-medical contexts, users commonly reference noticing effects on muscle fullness, strength, and joint comfort within the first 2-3 weeks of use.
There is no single blend that is universally best. Deca 200 mg/NPP 150 mg combines two nandrolone esters in a fixed ratio for both rapid and sustained release. The individual preparations Deca 300 (nandrolone decanoate) and NPP 150 (nandrolone phenylpropionate) are also referenced, allowing users to adjust the ratio of esters independently.
Deca 300 contains only nandrolone decanoate at 300 mg/mL, providing a single long-acting ester. Deca 200 mg/NPP 150 mg adds nandrolone phenylpropionate for a more rapid initial release alongside the sustained decanoate release. The dual-ester blend provides both rapid and prolonged nandrolone exposure.
A milligram amount cannot be classified as appropriate or excessive without considering the specific context, individual response, and other factors. In non-medical bodybuilding contexts, nandrolone esters are commonly referenced in the 200-400 mg per week range. Such use falls outside approved indications and nandrolone is known for significant side effect potential, including suppression of endogenous testosterone production.
Deca 200 mg/NPP 150 mg is labeled at 350 mg of total active compounds per mL, comprising 200 mg nandrolone decanoate and 150 mg nandrolone phenylpropionate per mL. It is supplied in a 10 mL vial, giving 3,500 mg of total labeled content per vial.
Yes. A published laboratory report dated March 20, 2026 measured Deca 200 mg/NPP 150 mg at 195.22 mg nandrolone decanoate and 146.96 mg nandrolone phenylpropionate, equivalent to 97.61% and 97.97% of label claim respectively.
The complete report can be viewed in the Lab Reports tab. Laboratory results apply to the tested sample represented by the individual report and should not be interpreted as a measurement of every vial.
Yes. Nandrolone and its esters are prohibited substances in sport and can be detected in urine for extended periods after use. Nandrolone decanoate has a particularly long detection time due to its long half-life of approximately 15 days. Athletes subject to drug testing should be aware that positive tests can result in sanctions.